The study is a Phase I, Single center, Randomized, Cross-over Double-blind Placebo-controlled
and Open-label Positive-controlled (moxifloxacin) in healthy volunteers.
The primary objective is to assess the cardiac safety after administration of P03277 to 48
healthy volunteers at dose of 0.1 mmol/kg (anticipated clinical dose) and 0.3 mmol/kg
(supra-clinical dose) by evaluating the QT and QTc intervals.
Phase:
Phase 1
Details
Lead Sponsor:
Guerbet
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination